{"id":6691,"date":"2026-07-17T11:06:10","date_gmt":"2026-07-17T11:06:10","guid":{"rendered":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/?p=6691"},"modified":"2026-07-17T11:06:11","modified_gmt":"2026-07-17T11:06:11","slug":"pemphix-study","status":"publish","type":"post","link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/pemphix-study\/","title":{"rendered":"The PEMPHIX Trial: Rituximab vs Mycophenolate for Pemphigus Vulgaris"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Pemphigus vulgaris is a rare autoimmune blistering disease that affects the skin and mucous membranes. If you develop this condition, your immune system mistakenly produces antibodies that attack the proteins responsible for keeping your skin cells attached to one another. As these connections break down, you may develop painful blisters and erosions on your skin and inside your mouth.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For many years, treatment relied mainly on corticosteroids combined with immunosuppressive medicines to control the disease. Although these treatments often helped reduce blistering, long-term steroid use could cause significant side effects. This created an important need for treatments that could provide better disease control while reducing your exposure to corticosteroids.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial, reported by Victoria P. Werth and an international group of investigators, directly compared rituximab with mycophenolate mofetil in adults with moderate-to-severe pemphigus vulgaris. The findings helped determine which treatment was more effective at achieving sustained complete remission at week 52 and continue to guide specialists when selecting treatment for people with moderate-to-severe pemphigus vulgaris.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What Was the PEMPHIX Trial?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial was an international Phase III clinical study involving people with moderate to severe pemphigus vulgaris. If you have this autoimmune blistering condition, the study was designed to identify which treatment could provide better sustained complete remission at week 52 while reducing reliance on corticosteroids.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers directly compared rituximab with mycophenolate mofetil, with both groups also receiving corticosteroids as part of their treatment. This allowed researchers to assess how each medicine performed when used alongside standard therapy and whether one approach could offer you greater benefits than the other.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study evaluated disease control, remission rates, safety and overall treatment outcomes. The findings provided important evidence that continues to help your specialist choose the most appropriate treatment for you, supporting more effective and personalised care for pemphigus vulgaris.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Why Was the Study Needed?<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Although corticosteroids remain highly effective for controlling pemphigus vulgaris, prolonged use can increase the risk of significant complications. If you need high doses of steroids for a long period, you may be more likely to develop side effects such as osteoporosis, diabetes, high blood pressure and an increased risk of infection.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Doctors therefore looked for treatments that could control the disease while reducing your long-term exposure to corticosteroids. The goal was to find therapies that not only managed blistering effectively but also helped you maintain disease control with fewer steroid-related complications.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial was designed to identify the most effective treatment strategy by comparing rituximab with mycophenolate mofetil. Its findings have helped your specialist make more informed treatment decisions, with the aim of achieving long-term remission while minimising the risks associated with prolonged steroid use.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Common Symptoms<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Many people with pemphigus vulgaris first develop painful sores inside the mouth before blisters appear on the skin. If you have the condition, these painful oral erosions may make eating, drinking and brushing your teeth uncomfortable, sometimes before any skin changes become noticeable.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The blisters are usually fragile and rupture easily, leaving raw areas that can be painful and may become infected if they are not managed appropriately. As new blisters continue to form, you may experience ongoing discomfort and find that your skin becomes increasingly sensitive.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">These symptoms can have a significant impact on your daily life. You may find it difficult to eat, speak or carry out normal activities comfortably, which is why early diagnosis and effective treatment are important for controlling the disease and improving your quality of life.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>When to Seek Prompt Medical Advice<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Seek prompt medical advice if blistered or eroded areas become increasingly painful, hot, swollen or begin producing yellow or green discharge. Fever, feeling acutely unwell, difficulty eating or drinking and signs of dehydration also require assessment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Widespread erosions can become infected, while painful mouth involvement may contribute to weight loss or malnutrition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How Rituximab Works<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Rituximab is a monoclonal antibody that targets CD20-positive B lymphocytes, a type of immune cell involved in the development of pemphigus vulgaris. If you receive rituximab, the treatment is designed to act on the cells that contribute to the abnormal immune response rather than simply treating the symptoms.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rituximab targets CD20-positive B lymphocytes involved in sustaining the abnormal autoimmune response. This reduces the population of CD20-positive B cells involved in the autoimmune response. Over time, this can reduce the generation of antibody-producing cells, although existing long-lived plasma cells are not directly removed. By reducing the number of these cells, rituximab helps decrease the production of damaging antibodies and limits the autoimmune activity responsible for your blisters.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As your immune response becomes better controlled, your skin and mucous membranes have the opportunity to heal and new blister formation may be reduced. This targeted approach has made rituximab an important treatment option for many people with moderate to severe pemphigus vulgaris.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>How Mycophenolate Mofetil Works<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Mycophenolate mofetil is an immunosuppressive medicine that works by reducing the activity of certain white blood cells involved in your immune response. If you have pemphigus vulgaris, this helps limit the immune system&#8217;s attack on your skin and mucous membranes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The medicine has been used for many years to treat a range of autoimmune diseases and is often prescribed alongside corticosteroids. By lowering immune activity, it can help reduce the production of harmful antibodies and improve control of your condition over time.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As inflammation becomes better controlled, you may develop fewer new blisters and your existing skin lesions may have a chance to heal. Your specialist will monitor your response to treatment and adjust your medication if needed to achieve the best possible disease control while minimising side effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>UK Prescribing Context<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rituximab has an authorised indication for the treatment of adults with moderate-to-severe pemphigus vulgaris. Mycophenolate products are licensed primarily for prevention of organ-transplant rejection, so their use for pemphigus is generally outside the licensed indication.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Off-label prescribing does not necessarily mean that a treatment is inappropriate. It means the prescriber should explain why the medicine is being recommended, the supporting evidence, alternatives, monitoring requirements and important risks.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Understanding Pemphigus Vulgaris<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"559\" src=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T120534.204-1024x559.jpg\" alt=\"\" class=\"wp-image-6697\" srcset=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T120534.204-1024x559.jpg 1024w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T120534.204-980x535.jpg 980w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T120534.204-480x262.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Pemphigus vulgaris is a rare autoimmune disease in which your immune system mistakenly produces antibodies that attack proteins called desmogleins. These proteins play an essential role in keeping your skin cells and the cells lining your mouth firmly attached to one another.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">When desmogleins are damaged, the connections between your skin cells weaken and begin to separate. As a result, you may develop fragile blisters that break easily, leaving painful erosions on your skin or inside your mouth that can interfere with eating, drinking and everyday activities.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Understanding how pemphigus vulgaris develops has helped researchers create more targeted treatments. Instead of only controlling the symptoms, newer therapies aim to reduce the abnormal immune response that causes your condition, helping you achieve better long-term disease control and, where possible, sustained remission.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Comparing Two Different Approaches<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial compared two different treatment strategies for moderate to severe pemphigus vulgaris. If you are being treated for this condition, your specialist may consider either a targeted biological therapy or a conventional immunosuppressive medicine depending on your individual circumstances.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers wanted to determine whether rituximab could provide better disease control than mycophenolate mofetil while maintaining an acceptable safety profile. They carefully assessed how well each treatment controlled blistering, reduced disease activity and helped patients achieve remission.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This direct comparison provided valuable clinical evidence that has influenced modern treatment decisions. The results continue to help your specialist choose the most appropriate therapy for you, balancing the potential benefits of treatment with your overall health and long-term management goals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>PEMPHIX Trial Design and 52-Week Results<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Trial feature<\/strong><\/td><td><strong>Rituximab group<\/strong><\/td><td><strong>Mycophenolate mofetil group<\/strong><\/td><td><strong>What the finding means<\/strong><\/td><\/tr><\/thead><tbody><tr><td>Treatment allocation<\/td><td>67 participants were randomised to rituximab<\/td><td>68 participants were randomised to mycophenolate mofetil<\/td><td>The trial included 135 adults with moderate-to-severe pemphigus vulgaris.<\/td><\/tr><tr><td>Study design<\/td><td>Intravenous rituximab plus an oral corticosteroid taper<\/td><td>Oral mycophenolate mofetil plus the same planned corticosteroid taper<\/td><td>This was a randomised, double-blind, double-dummy Phase III comparison.<\/td><\/tr><tr><td>Trial treatment<\/td><td>Rituximab 1,000 mg on days 1 and 15, repeated at weeks 24 and 26<\/td><td>Mycophenolate mofetil 2 g daily for 52 weeks<\/td><td>The results relate to these trial regimens and should not be applied automatically to different doses or schedules.<\/td><\/tr><tr><td>Primary endpoint<\/td><td>Sustained complete remission at week 52<\/td><td>Sustained complete remission at week 52<\/td><td>Remission required healed lesions, no new active lesions and no oral corticosteroids for at least 16 consecutive weeks.<\/td><\/tr><tr><td>Sustained complete remission<\/td><td>25 of 62 participants, approximately 40%<\/td><td>6 of 63 participants, approximately 10%<\/td><td>Rituximab was more effective for the strict primary remission endpoint, but most participants in both groups did not achieve it.<\/td><\/tr><tr><td>Mean cumulative corticosteroid dose<\/td><td>3,545 mg<\/td><td>5,140 mg<\/td><td>Rituximab reduced average corticosteroid exposure, but it did not remove the need for corticosteroids at the beginning of treatment.<\/td><\/tr><tr><td>Disease flares<\/td><td>6 flares were recorded<\/td><td>44 flares were recorded<\/td><td>Disease flares were less frequent with rituximab during the 52-week treatment period.<\/td><\/tr><tr><td>Quality-of-life score<\/td><td>Mean reduction in DLQI score: 8.87 points<\/td><td>Mean DLQI improvement of 6.00 points<\/td><td>Quality of life improved in both groups, with a greater average improvement in the rituximab group.<\/td><\/tr><tr><td>Serious adverse events<\/td><td>Occurred in 15 of 67 participants, approximately 22%<\/td><td>Occurred in 10 of 68 participants, approximately 15%<\/td><td>The efficacy advantage should be considered alongside the higher observed proportion of serious adverse events with rituximab.<\/td><\/tr><tr><td>Duration of comparison<\/td><td>52 weeks<\/td><td>52 weeks<\/td><td>The trial did not establish comparative effectiveness or safety beyond one year<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Improving Quality of Life<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"559\" src=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T114417.691-1024x559.jpg\" alt=\"\" class=\"wp-image-6695\" srcset=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T114417.691-1024x559.jpg 1024w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T114417.691-980x535.jpg 980w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T114417.691-480x262.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Effective treatment for pemphigus vulgaris aims not only to control blister formation but also to improve your overall quality of life. If your symptoms are well managed, you may experience less pain and discomfort, making everyday activities easier and more comfortable.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Reducing painful mouth sores, improving your ability to eat and speak, and preventing disease relapses can make a significant difference to your daily routine. Better disease control may also help you regain confidence and return to work, social activities and other parts of your normal life.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sustained complete remission at week 52 remains the primary objective of treatment. Your specialist will work with you to achieve lasting remission while reducing symptoms, limiting treatment side effects and helping you maintain the best possible quality of life.<strong>Achieving Sustained Remission<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The primary endpoint was sustained complete remission at week 52, defined as complete lesion healing with no new active lesions for at least 16 consecutive weeks while taking no oral corticosteroids. If you have pemphigus vulgaris, reaching sustained complete remission at week 52 with little or no ongoing disease activity is one of the main goals of treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study found that a larger proportion of participants treated with rituximab achieved the strict primary remission endpoint than those receiving mycophenolate mofetil. However, approximately six out of ten participants in the modified intention-to-treat rituximab group did not achieve sustained complete remission under this definition. However, approximately six out of ten participants in the modified intention-to-treat rituximab group did not achieve sustained complete remission under this definition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This was one of the most important findings of the PEMPHIX trial and has had a significant influence on the management of pemphigus vulgaris. The results continue to help your specialist select treatments that give you the best opportunity to achieve long-term remission while reducing the need for prolonged corticosteroid use.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Reduced Disease Activity<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Patients receiving rituximab generally experienced greater reductions in disease activity throughout the PEMPHIX trial. Clinical trial participants receiving rituximab generally experienced greater reductions in disease activity than those receiving mycophenolate mofetil. Participants treated with rituximab also experienced fewer disease flares during the study, contributing to improved overall disease control.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Many participants achieved improved blister control and experienced fewer disease relapses during the study. Better control of your condition can allow your skin and mucous membranes to heal more effectively while reducing the disruption caused by repeated flare-ups.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Improved disease stability can benefit both your physical and emotional wellbeing. When your symptoms are well controlled, you may find everyday activities such as eating, speaking and socialising more comfortable, helping to improve your overall quality of life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Corticosteroid Reduction<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Reducing corticosteroid exposure was another important goal of the PEMPHIX trial. Although steroids are highly effective at controlling pemphigus vulgaris, taking them for long periods can increase the risk of unwanted side effects. Finding ways to reduce your overall steroid use is therefore an important part of long-term treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study showed that patients treated with rituximab often required lower cumulative doses of corticosteroids than those receiving mycophenolate mofetil. If your disease can be controlled with less reliance on steroids, you may still achieve good symptom control while limiting your exposure to these medicines.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lower cumulative exposure would generally be expected to reduce some steroid-related risks, but PEMPHIX did not establish that every long-term steroid complication was prevented. Individual risk also depends on the dose, duration, age, underlying health and use of preventive measures. Your specialist will aim to manage your condition using the lowest effective steroid dose while choosing additional treatments that help you maintain sustained complete remission at week 52.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Understanding Side Effects<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Both rituximab and mycophenolate mofetil can cause side effects because they affect your immune system. While these medicines help control pemphigus vulgaris, they can also reduce your body&#8217;s ability to fight infections, so careful management is an important part of your treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Potential side effects include infections, infusion reactions with rituximab and changes in your blood counts. Not everyone experiences these problems, but you should tell your specialist if you develop symptoms such as fever, persistent illness or any new concerns during treatment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Careful monitoring remains essential throughout your treatment. Your specialist will arrange regular appointments and blood tests to check how well the medicine is working, monitor your overall health and identify any side effects as early as possible.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Individualised Treatment Decisions<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pemphigus vulgaris does not affect everyone in the same way, so treatment plans are tailored to each person\u2019s needs. Your specialist considers several factors before recommending the most suitable approach. This personalised strategy helps balance disease control with reducing potential treatment risks.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Severity<\/strong><strong>:<\/strong> The extent and severity of your symptoms influence which treatments may be most appropriate.<\/li>\n\n\n\n<li><strong>Previous Treatments<\/strong><strong>:<\/strong> Your response to earlier therapies helps guide future treatment decisions.<\/li>\n\n\n\n<li><strong>Overall Health Factors<\/strong><strong>:<\/strong> Your general health and personal circumstances are considered when planning your care.<\/li>\n\n\n\n<li><strong>Treatment Goals and Monitoring<\/strong><strong>:<\/strong> Your healthcare team adjusts treatment based on your progress and response over time.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Overall, personalised management is an important part of modern pemphigus care. A treatment plan designed around your symptoms, health, and goals can help achieve better disease control while supporting your long-term wellbeing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Importance of Specialist Care<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Pemphigus vulgaris is a complex autoimmune disease that requires expert diagnosis and long-term management. If you have this condition, receiving care from a specialist dermatologist can help ensure that your diagnosis is accurate and your treatment is appropriate for the severity of your disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Your specialist will monitor your disease activity, assess how well your treatment is working and watch for any possible medication side effects. By reviewing your progress regularly, they can adjust your treatment plan if your symptoms change or if you need additional support.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Regular follow-up appointments are an important part of your ongoing care. These visits help your specialist keep your condition under control, identify any complications early and support you in achieving the best possible long-term outcome while maintaining your overall health.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Influence on Clinical Guidelines<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"559\" src=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T115907.303-1024x559.jpg\" alt=\"\" class=\"wp-image-6696\" srcset=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T115907.303-1024x559.jpg 1024w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T115907.303-980x535.jpg 980w, https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T115907.303-480x262.jpg 480w\" sizes=\"(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1024px, 100vw\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial provided important clinical evidence supporting the use of rituximab for the treatment of pemphigus vulgaris. If you are being treated for this condition today, your specialist may use the findings from this study to help select the treatment that offers you the best chance of achieving sustained complete remission at week 52.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The results of the trial have influenced international treatment recommendations by demonstrating that rituximab can provide higher rates of sustained remission than mycophenolate mofetil in many patients. This evidence has helped clinicians make more informed decisions when choosing the most appropriate therapy for you.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The findings have contributed to modern international treatment recommendations alongside evidence from other randomised trials and subsequent guideline updates.By following these evidence-based guidelines, your healthcare team can provide treatment that reflects the latest research while tailoring your care to your individual needs and overall health.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Continuing Research<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers continue exploring new treatments for pemphigus vulgaris and other autoimmune blistering diseases. As medical research advances, you may benefit from therapies that provide better disease control, longer-lasting remission and a more targeted approach to managing your condition.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Current studies are investigating new biological medicines and targeted immune therapies that act on specific parts of your immune system. By focusing on the underlying cause of the disease, these treatments aim to control blister formation more effectively while reducing damage to healthy tissues.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The overall goal of this research is to improve disease control while minimising treatment-related side effects. As new evidence becomes available, your specialist may have access to additional treatment options that can be tailored to your individual needs and help improve your long-term quality of life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Advances in Personalised Medicine<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Modern dermatology increasingly focuses on personalised treatment strategies rather than using the same approach for every patient. If you have pemphigus vulgaris, your specialist will consider your individual disease pattern, overall health and treatment history when deciding which therapy is most suitable for you.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Researchers are learning more about how individual immune responses influence autoimmune diseases. This growing understanding may allow future therapies to target the specific immune pathways affecting your condition, helping you achieve better disease control with fewer treatment-related side effects.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial reflects this broader shift towards personalised medicine in autoimmune disease management. Its findings have helped your specialist choose treatments based on the best available evidence while tailoring your care to your individual needs and long-term treatment goals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Lasting Legacy of the PEMPHIX Trial<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial provided high-quality clinical evidence by directly comparing two widely used treatments for pemphigus vulgaris. If you are discussing treatment options with your specialist, the findings from this study continue to provide valuable guidance when selecting the most appropriate therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The results helped clarify the role of rituximab in achieving long-term remission and demonstrated that it could provide better sustained disease control than mycophenolate mofetil for many patients. This evidence has given your specialist greater confidence in recommending treatment strategies that aim to reduce disease activity and limit long-term corticosteroid use.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Today, the PEMPHIX trial remains one of the most influential clinical studies in pemphigus vulgaris. Its findings continue to shape clinical practice, support international treatment guidelines and help your healthcare team provide evidence-based care that is tailored to your individual needs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>What the Findings Mean for Patients<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The findings from the PEMPHIX trial offer reassurance that treatment options for pemphigus vulgaris continue to improve. If you are living with this condition, you now have access to therapies that are supported by strong clinical evidence and designed to provide better sustained complete remission at week 52.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Advances in biological therapies have expanded the treatment choices available to you and have helped many patients achieve longer periods of remission with reduced reliance on corticosteroids. Your specialist can use these developments to recommend a treatment plan that is tailored to your condition, symptoms and overall health.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ongoing research continues to refine the long-term management of pemphigus vulgaris. As new therapies and clinical evidence emerge, you may benefit from more targeted treatments that improve disease control, reduce side effects and support a better quality of life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Looking Ahead<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial transformed the understanding of how pemphigus vulgaris can be managed by demonstrating the benefits of targeted biological therapy compared with conventional immunosuppression. If you are diagnosed with this condition today, the findings from this landmark study may help your specialist choose a treatment that offers better sustained complete remission at week 52 and reduced reliance on corticosteroids.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The evidence from the trial continues to influence modern clinical practice and supports the growing use of targeted biological therapies in appropriate patients. By using treatments that address the underlying immune response, your healthcare team can develop a more personalised management plan that is tailored to your individual needs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As research continues, you may benefit from even more precise therapies that improve remission rates while reducing treatment-related side effects. The PEMPHIX trial has laid an important foundation for future advances and will continue to guide specialists in delivering evidence-based care for people living with pemphigus vulgaris.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Myth vs Fact:<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Myth<\/strong><\/td><td><strong>Fact<\/strong><\/td><\/tr><tr><td>PEMPHIX compared rituximab and mycophenolate without corticosteroids.<\/td><td>Both groups received the same planned oral corticosteroid taper.<\/td><\/tr><tr><td>Every rituximab-treated participant achieved remission.<\/td><td>Sustained complete remission occurred in approximately 40% of the rituximab group.<\/td><\/tr><tr><td>Mycophenolate did not work for anyone.<\/td><td>Approximately 10% achieved the strict primary remission endpoint, and others may have experienced partial improvement.<\/td><\/tr><tr><td>The trial proved that rituximab was safer.<\/td><td>Serious adverse events occurred in 22% with rituximab and 15% with mycophenolate.<\/td><\/tr><tr><td>Rituximab eliminated the need for corticosteroids immediately.<\/td><td>Participants began with corticosteroids and followed a planned taper.<\/td><\/tr><tr><td>A lower steroid dose proves that every steroid complication was prevented.<\/td><td>The trial measured cumulative steroid exposure, not reductions in every long-term complication.<\/td><\/tr><tr><td>The trial established results beyond several years.<\/td><td>The formal comparative treatment period lasted 52 weeks.<\/td><\/tr><tr><td>Rituximab permanently cures pemphigus vulgaris.<\/td><td>It can produce remission, but relapses may occur and maintenance or retreatment may be needed.<\/td><\/tr><tr><td>Rituximab removes every antibody-producing cell.<\/td><td>It targets CD20-positive B cells but does not directly deplete every mature plasma cell.<\/td><\/tr><tr><td>Mycophenolate is licensed specifically for pemphigus in the UK.<\/td><td>It is commonly used off-label as a steroid-sparing immunosuppressant.<\/td><\/tr><tr><td>Both medicines have the same risks.<\/td><td>They suppress the immune system differently and have distinct monitoring, pregnancy and infusion considerations.<\/td><\/tr><tr><td>PEMPHIX alone established rituximab as first-line treatment.<\/td><td>Rituximab\u2019s role was already supported by earlier trial evidence, licensing decisions and international recommendations. PEMPHIX strengthened the direct comparison with mycophenolate mofetil.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Takeaways<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>PEMPHIX was a randomised, double-blind and double-dummy Phase III trial.<\/li>\n\n\n\n<li>It randomised 135 adults with moderate-to-severe pemphigus vulgaris.<\/li>\n\n\n\n<li>Rituximab was compared directly with mycophenolate mofetil.<\/li>\n\n\n\n<li>Both groups received the same corticosteroid-tapering regimen.<\/li>\n\n\n\n<li>Sustained complete remission occurred in 40.3% with rituximab and 9.5% with mycophenolate.<\/li>\n\n\n\n<li>Mean cumulative corticosteroid exposure was lower with rituximab.<\/li>\n\n\n\n<li>Six disease flares occurred with rituximab compared with 44 with mycophenolate.<\/li>\n\n\n\n<li>Quality-of-life improvement was greater with rituximab.<\/li>\n\n\n\n<li>Serious adverse events occurred in 22% with rituximab and 15% with mycophenolate.<\/li>\n\n\n\n<li>Comparative outcomes beyond 52 weeks were not established.<\/li>\n\n\n\n<li>Rituximab requires infusion supervision and hepatitis B screening.<\/li>\n\n\n\n<li>Rare but serious rituximab complications include PML and severe infection.<\/li>\n\n\n\n<li>Mycophenolate is strongly teratogenic and requires pregnancy-prevention measures.<\/li>\n\n\n\n<li>Mycophenolate use for pemphigus is generally off-label in the UK.<\/li>\n\n\n\n<li>Treatment should be coordinated by a dermatologist experienced in autoimmune blistering disease.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>FAQs:<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>1. What was the PEMPHIX trial?<\/strong><br>The PEMPHIX trial was an international Phase III clinical study that compared rituximab with mycophenolate mofetil in people with moderate to severe pemphigus vulgaris. Both treatment groups also received corticosteroids, allowing researchers to compare disease control, remission rates and safety.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>2. What is pemphigus vulgaris?<\/strong><br>Pemphigus vulgaris is a rare autoimmune blistering disease in which the immune system produces antibodies that attack proteins responsible for holding skin cells together. This leads to fragile blisters and painful erosions affecting the skin and mucous membranes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>3. Why was the PEMPHIX trial important?<\/strong><br>The trial provided high-quality evidence comparing two commonly used treatments for pemphigus vulgaris. It demonstrated that rituximab achieved higher rates of sustained complete remission than mycophenolate mofetil, strengthening the direct comparative evidence available to specialists.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>4. How does rituximab work in pemphigus vulgaris?<\/strong><br>Rituximab is a monoclonal antibody that <strong>Rituximab is a monoclonal antibody that targets CD20-positive B cells involved in the autoimmune response. By reducing these cells, it helps decrease the production of pathogenic antibodies and improve disease control. <\/strong>Reducing these cells helps decrease autoimmune activity and improve disease control.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>5. How does mycophenolate mofetil work?<\/strong><br>Mycophenolate mofetil suppresses the immune system by reducing the activity and growth of certain white blood cells. It helps control inflammation and blister formation but works through a broader immunosuppressive effect than rituximab.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>6. Did rituximab reduce the need for corticosteroids?<\/strong><br>Yes. The PEMPHIX trial found that patients treated with rituximab generally required lower cumulative doses of corticosteroids than those receiving mycophenolate mofetil. Reducing steroid exposure may help lower the risk of long-term steroid-related complications. The trial showed lower cumulative exposure, but it did not prove that every steroid-related complication was prevented.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>7. Are rituximab and mycophenolate mofetil associated with side effects?<\/strong><br>Yes, Rituximab may cause infusion reactions, infection, hepatitis B reactivation, reduced immunoglobulin levels and very rare PML. Mycophenolate may cause gastrointestinal symptoms, infections and blood-count, liver or kidney abnormalities. It is also strongly teratogenic. The medicines therefore require different screening, monitoring and pregnancy precautions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>8. Is rituximab now considered a standard treatment for pemphigus vulgaris?<\/strong><br>Following evidence from studies including the PEMPHIX trial, rituximab is recommended in several international guidelines for many patients with moderate to severe pemphigus vulgaris and is included in several international clinical guidelines. It is not automatically suitable for every patient, and treatment choice should consider infection risk, previous therapy, pregnancy plans, comorbidities and access to infusion services.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>9. Can pemphigus vulgaris be cured?<\/strong><br>There is currently no permanent cure for pemphigus vulgaris. However, modern treatments can often achieve long-term remission, reduce blister formation and significantly improve quality of life when managed by an experienced specialist.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>10. When should you see a dermatologist for pemphigus vulgaris?<\/strong><br>You should seek assessment from a dermatologist if you develop persistent painful oral erosions, fragile blisters, widespread skin erosions or symptoms suggestive of pemphigus vulgaris. Early diagnosis and specialist treatment can help control the disease more effectively and reduce the risk of complications. Seek prompt medical care if blistered areas become hot, increasingly painful or produce pus, or if mouth involvement prevents adequate eating or drinking.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Final Thoughts: The Lasting Impact of the PEMPHIX Trial<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The PEMPHIX trial marked an important step forward in the treatment of pemphigus vulgaris by demonstrating that targeted biological therapy with rituximab could achieve higher rates of sustained remission than mycophenolate mofetil in many patients. Its findings have helped reshape modern treatment strategies, offering new opportunities to improve disease control while reducing long-term reliance on corticosteroids.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The study also reinforced the importance of personalised care, recognising that treatment decisions should be based on factors such as disease severity, overall health, and individual response to therapy. As research into autoimmune blistering diseases continues to advance, the PEMPHIX trial remains a key foundation for developing safer and more effective treatments. <a href=\"https:\/\/www.london-dermatology-centre.co.uk\/\" title=\"\">If you would like to book a consultation with one of our Dermatologist in London<\/a>, you can contact us at the London Dermatology Centre.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>References:<\/strong><\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Werth, V.P., Joly, P., Mimouni, D., Maverakis, E., Caux, F., Lehane, P., Gearhart, L., Kapre, A., Pordeli, P. and Chen, D.M., for the PEMPHIX Study Group (2021) \u2018Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris\u2019, The New England Journal of Medicine, 384(24), pp. 2295\u20132305. Available at: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34097368\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34097368\/<\/a><\/li>\n\n\n\n<li>Malik, A.M., Tupchong, S., Huang, S., Are, A., Hsu, S. and Motaparthi, K. (2021) \u2018An updated review of pemphigus diseases\u2019, Medicina, 57(10), article 1080. Available at: <a href=\"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1080\">https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1080<\/a><\/li>\n\n\n\n<li>Joly, P., Horvath, B., Patsatsi, A. et al. (2020) \u2018Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European Academy of Dermatology and Venereology\u2019, Journal of the European Academy of Dermatology and Venereology, 34(9), pp. 1900\u20131913. Available at: <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/32830877\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/32830877\/<\/a><\/li>\n\n\n\n<li>Khandelwal, K., Jajoo, V., Bajpai, K., Madke, B., Prasad, R., Wanjari, M.B. et al. (2023) \u2018Rituximab in pemphigus vulgaris: a review of monoclonal antibody therapy in dermatology\u2019, Cureus, 15(6), article e40734. Available at: <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10361785\/\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10361785\/<\/a><\/li>\n\n\n\n<li>Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., Calbo, S. et al. (2017) \u2018First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial\u2019, The Lancet, 389(10083), pp. 2031\u20132040. Available at: <a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0140673617300703\">https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0140673617300703<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Pemphigus vulgaris is a rare autoimmune blistering disease that affects the skin and mucous membranes. If you develop this condition, your immune system mistakenly produces antibodies that attack the proteins responsible for keeping your skin cells attached to one another. As these connections break down, you may develop painful blisters and erosions on your skin [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":6698,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6691","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"acf":[],"aioseo_notices":[],"rttpg_featured_image_url":{"full":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227.jpg",1100,600,false],"landscape":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227.jpg",1100,600,false],"portraits":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227.jpg",1100,600,false],"thumbnail":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-150x150.jpg",150,150,true],"medium":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-300x164.jpg",300,164,true],"large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-1024x559.jpg",1024,559,true],"1536x1536":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227.jpg",1100,600,false],"2048x2048":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227.jpg",1100,600,false],"et-pb-post-main-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-400x250.jpg",400,250,true],"et-pb-post-main-image-fullwidth":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-1080x600.jpg",1080,600,true],"et-pb-portfolio-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-400x284.jpg",400,284,true],"et-pb-portfolio-module-image":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-510x382.jpg",510,382,true],"et-pb-portfolio-image-single":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-1080x589.jpg",1080,589,true],"et-pb-gallery-module-image-portrait":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-400x516.jpg",400,516,true],"et-pb-post-main-image-fullwidth-large":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227.jpg",1100,600,false],"et-pb-image--responsive--desktop":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227.jpg",1100,600,false],"et-pb-image--responsive--tablet":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-980x535.jpg",980,535,true],"et-pb-image--responsive--phone":["https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-content\/uploads\/2026\/07\/Imagess-2026-07-17T121354.227-480x262.jpg",480,262,true]},"rttpg_author":{"display_name":"Shailendra Kumar","author_link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/author\/shailendra\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.london-dermatology-centre.co.uk\/blog\/category\/uncategorized\/\" rel=\"category tag\">Uncategorized<\/a>","rttpg_excerpt":"Pemphigus vulgaris is a rare autoimmune blistering disease that affects the skin and mucous membranes. If you develop this condition, your immune system mistakenly produces antibodies that attack the proteins responsible for keeping your skin cells attached to one another. As these connections break down, you may develop painful blisters and erosions on your skin&hellip;","_links":{"self":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/comments?post=6691"}],"version-history":[{"count":5,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6691\/revisions"}],"predecessor-version":[{"id":6709,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/posts\/6691\/revisions\/6709"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media\/6698"}],"wp:attachment":[{"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/media?parent=6691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/categories?post=6691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/wp-json\/wp\/v2\/tags?post=6691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}